Literature DB >> 31097066

Cost-effectiveness of tuberculosis screening for migrant children in a low-incidence country.

J Usemann1, M Ledergerber2, G Fink3, N Ritz4.   

Abstract

<sec id="st1"> <title>BACKGROUND</title> Detection of latent tuberculous infection (LTBI) is important to prevent progression to active tuberculosis (TB), particularly in migrant children. We evaluated the cost-effectiveness of TB screening in migrant children in a low-incidence country. </sec> <sec id="st2"> <title>METHODS</title> Retrospective analysis of a school-based TB screening programme in Switzerland. Migrant children were screened using the tuberculin skin test (TST). TST was considered positive if induration was 10 mm in non-bacille Calmette-Guérin (BCG) vaccinated children, and 15 mm in BCG-vaccinated children. Screening and treatment costs were extracted from hospital records. Cost impact was analysed as the difference between the cost of treatment for active TB and screening plus LTBI treatment. Cost per disability-adjusted life-years (DALY) was assessed based on Global Burden of Disease disability weight estimates. </sec> <sec id="st3"> <title>RESULTS</title> Of 1462 children screened, 1120 (77%; mean age 10.9 years; 46% female) underwent a TST. TST induration of 10 mm was documented in 78 (6.9%), and TST induration of 15 mm in 19 (1.6%). Twenty-one were TST-positive, and 17 children were diagnosed with LTBI; none had active TB. The highest rates of TST induration 10 mm were found in migrant children from Africa (16.6%) and Turkey (15.4%). Screening for LTBI was cost-effective if LTBI prevalence was 14%, with a progression rate of 5%; in case of lower LTBI prevalence, LTBI screening is cost-effective if progression rates to active TB are higher. </sec> <sec id="st4"> <title>CONCLUSION</title> School-based TB screening programmes targeting migrant children are cost-effective if populations with a relatively increased LTBI prevalence and/or high progression rates are included. </sec>.

Entities:  

Mesh:

Year:  2019        PMID: 31097066     DOI: 10.5588/ijtld.18.0356

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

Review 1.  A scoping review of paediatric latent tuberculosis infection care cascades: initial steps are lacking.

Authors:  Jeffrey I Campbell; Thomas J Sandora; Jessica E Haberer
Journal:  BMJ Glob Health       Date:  2021-05

Review 2.  Health needs of refugee children identified on arrival in reception countries: a systematic review and meta-analysis.

Authors:  Albertine Baauw; Joana Kist-van Holthe; Bridget Slattery; Martijn Heymans; Mai Chinapaw; Hans van Goudoever
Journal:  BMJ Paediatr Open       Date:  2019-09-11

3.  Strengthening Tuberculosis Services for Children and Adolescents in Low Endemic Settings.

Authors:  Jeffrey R Starke; Connie Erkens; Nicole Ritz; Ian Kitai
Journal:  Pathogens       Date:  2022-01-26

4.  Framing the detection of incipient tuberculosis infection: A qualitative study of political prioritisation.

Authors:  Rosemary James; Grant Theron; Frank Cobelens; Nora Engel
Journal:  Trop Med Int Health       Date:  2022-02-22       Impact factor: 3.918

5.  Pediatric Tuberculosis Disease during Years of High Refugee Arrivals: A 6-Year National Prospective Surveillance Study.

Authors:  Nora Fritschi; Axel J Schmidt; Jürg Hammer; Nicole Ritz
Journal:  Respiration       Date:  2021-07-29       Impact factor: 3.580

6.  Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis.

Authors:  Kieran Rustage; Jessica Lobe; Sally E Hayward; Kristina L Kristensen; Ioana Margineanu; Ymkje Stienstra; Delia Goletti; Dominik Zenner; Teymur Noori; Manish Pareek; Christina Greenaway; Jon S Friedland; Laura B Nellums; Sally Hargreaves
Journal:  Lancet Infect Dis       Date:  2021-08-04       Impact factor: 25.071

Review 7.  Infectious Diseases among Refugee Children.

Authors:  Avinash K Shetty
Journal:  Children (Basel)       Date:  2019-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.